12:00 AM
 | 
Sep 08, 2008
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 9/5 cls
AMAG (NASDAQ:AMAG) Ladenburg Thalmann Juan Sanchez New Buy 2% $39.31
Needham Mark Monane New Buy
Sanchez set a $63 price target. He thinks there is an 80% chance that FDA will approve an NDA in October for AMAG's ferumoxytol to treat iron deficiency anemia in CKD patients. He thinks investor concerns about the adequacy of available data are exaggerated.
Monane set an $80 target. He said he is "positively inclined" towards FDA approval for AMAG's ferumoxytol in October. He thinks the company will need a partner to commercialize the agent outside the U.S.
Amylin (NASDAQ:AMLN) Lazard Matthew Osborne Upgrade Buy (from hold) -4%

Read the full 875 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >